drugset / Trial / NCT04809103
Intratumoral Cisplatin for Resectable NSCLC
Non-randomizedSequentialOpen-labelTreatment
Summary
PRIMARY OBJECTIVE: To identify the maximum tolerated dose (MTD) of intratumoral cisplatin, delivered during a single bronchoscopy with cone-beam CT confirmation, in a dose escalation protocol DESIGN: 3+3 dose escalation.
Timeline
- Start
- 2021-03-08
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 10 mg | Other |
| Subject | Cisplatin | Other / unclassified | 20 mg | Other |